- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01628497
Exhaled NO Testing in Filariasis
Tutkimuksen yleiskatsaus
Tila
Ehdot
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Region 4
-
Georgetown, Region 4, Guyana
- Georgetown Public Hospital Corporation
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Study subjects:
- recruited from patients with a chief complaint of wheezing, asthma or cough.
- assessed by a physician prior to consideration for enrollment into the study
- screened by the study investigator after evaluation by the physician
Control subjects:
Controls will be matched with cases by gender, age and region of residence. They will have non-emergent complaints without respiratory symptoms.
Kuvaus
Inclusion Criteria:
- Age 6 years or older of either gender
- Patients presenting with pulmonary symptoms a. Confirmed or suspected asthma patients: i. Patients presenting with symptoms consistent with an acute exacerbation of asthma, including:
1. Wheezing 2. Shortness of breath 3. Chest tightness 4. Cough ii. Disposition to the asthma room after triage and physician evaluation (disposition to other areas of the A&E allowed if due to no available space in the asthma room) iii. Patients are potentially eligible with or without a past history of health care provider diagnosed asthma iv. Patients are potentially eligible regardless of the number of previous episodes of wheezing (i.e. patients with a first episode of bronchospasm are potentially eligible) v. If suspected or documented to have pneumonia or a pulmonary infiltrate, patients are potentially eligible if:
- They have a dry cough (no production of purulent sputum)
- They have bronchospasm as manifested by wheezing or need for salbutamol (albuterol) breathing treatments vi. Patients with wheezing are not eligible if they:
1. Have purulent sputum production 2. Have known or suspected:
a. Tuberculosis b. Immunodeficiency c. Congestive heart failure d. Foreign body aspiration b. Patients presenting with a chief complaint of cough: i. Potentially eligible patients will have a cough of greater than one week (seven days) duration ii. Asthma room disposition is not required for these subjects iii. If suspected or documented to have pneumonia or a pulmonary infiltrate, patients are potentially eligible if:
1. They have a dry cough (no production of purulent sputum) iv. Patients with cough are not eligible if:
- Have purulent sputum production
Have known or suspected:
- Tuberculosis
- Immunodeficiency
- Congestive heart failure
- Foreign body aspiration
- Patients will be medically stable at the time of the consent process (see exclusion criteria below)
- A minimum of 2 years of continuous residence in Guyana at the time of enrollment, exclusive of short trips out of the country (at least 21 of previous 24 months physically in Guyana)
- English speaking
Exclusion Criteria:
- Patients less than 6 years of age
- Patients who do not consent to the study
- Children (<18 years) without a parent/guardian present
- Prisoners
Patients who appear to be medically or psychologically unstable or felt to be otherwise inappropriate for study enrollment, in the opinion of the investigator or any treating health care provider. This determination will be made on an individual basis, but some of the general criteria to be used in making this determination will be:
i. The patient appears to be in significant pain ii. The patient appears acutely ill - severe respiratory distress, diaphoretic, altered mental status, active bleeding, actively vomiting, etc.
iii. Those with respiratory difficulty to the point they cannot speak in complete sentences iv. Chief complaint of sexual assault v. The patient appears acutely intoxicated vi. The patient displays agitated, nervous, restless, or other behavior suggestive of an uncontrolled psychiatric emergency
- Patients with pulmonary findings felt to be secondary to congestive heart failure, foreign body, bacterial pneumonia, tuberculosis or other clearly defined cause
- Non-English speaking patients
- Patients without at least 2 years of residence (exclusive of short trips abroad, total of 21 of 24 previous months physically in Guyana) in Guyana at the time of enrollment
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
---|
Positive filariasis test
Those testing positive for filariasis
|
Filariasis negative
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- Fil-01
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Filariasis
-
Drugs for Neglected DiseasesBayer; Bill and Melinda Gates FoundationValmisFilariasisYhdistynyt kuningaskunta
-
University of WashingtonLondon School of Hygiene and Tropical Medicine; National Institute of Allergy... ja muut yhteistyökumppanitAktiivinen, ei rekrytointiFilariasis | HelmintiaasiIntia, Benin, Malawi
-
Drugs for Neglected DiseasesBayer; Bill and Melinda Gates FoundationValmisFilariasisYhdistynyt kuningaskunta
-
Washington University School of MedicineCenter for Research on Filariasis and Other Tropical Diseases, CameroonValmis
-
National Institute of Allergy and Infectious Diseases...Valmis
-
National Institute of Allergy and Infectious Diseases...Lopetettu
-
Programme National de Lutte contre l'Onchocercose...Institut de Recherche pour le DeveloppementEi vielä rekrytointia
-
National Institute of Allergy and Infectious Diseases...Valmis
-
Swiss Tropical & Public Health InstituteDrugs for Neglected Diseases; Ifakara Health InstituteValmis
-
National Institute of Allergy and Infectious Diseases...Valmis